BPC-157 side effects: an empty file is not a clean one
Ask what BPC-157 does to people and the honest answer is that nobody has looked. Forty-nine of its 228 PubMed records use a safety word; twenty of those are indexed as being about humans; none of them is a trial. The FDA's own entry says the agency lacks enough information to know whether the peptide would cause harm. Sellers read that as reassurance. It is the opposite of one.
What this comes down to
- Zero clinical trials of BPC-157 are indexed in PubMed, so no side-effect rate has ever been measured against a placebo.
- Of the 228 records, 162 carry PubMed's animal indexing tag. The safety literature that exists is largely rat work.
- The FDA names specific serious adverse events for CJC-1295 and for ipamorelin on the same page. For BPC-157 it names none — because it has none, not because there are none.
- Two 2026 reviews in the orthopedic and sports medicine literature reach the same place: promising animal data, scarce human safety data, real potential for harm.
What is actually in the file
BPC-157 has a large literature and no human safety data, which sounds like a contradiction until you look at what the literature is. Two hundred and twenty-eight records. A hundred and sixty-two of them carry PubMed's animal indexing tag. Forty-nine use a safety, adverse, toxicity or tolerability term somewhere in the title or abstract, and twenty of those are indexed as being about humans — which marks a paper as concerning people, not as having given anyone the drug. Run the trial filter and the whole thing collapses to nothing[1]. The approval side of that story is its own article; this one is only about harm.
PubMed, via the E-utilities API
"BPC 157" AND (safety[tiab] OR adverse[tiab] OR toxicity[tiab] OR tolerability[tiab])
Returned 49. Positive control — semaglutide, identical safety terms — returned 2088 through the identical filter in the same session.
Narrowed to PubMed's human indexing tag, BPC-157 drops to 20 and semaglutide to a number far larger than anything here. Using MeSH adverse-effects and toxicity subheadings instead returns 36 for BPC-157 against 1,110 for semaglutide. Three different rulers, the same shape of answer: the material exists, and it is not about people taking this peptide.
Forty-nine papers mentioning safety reads like a body of evidence and isn't one. A rat study reporting that a dose was tolerated is a safety word in a database field. It tells you nothing about what happens when an adult injects a compounded version of the same molecule every day for a year, which is what is actually being sold.
The FDA says nothing about BPC-157, and says a lot about its neighbors
The most useful thing on the FDA's compounding page isn't what it says about BPC-157. It's what it says about the peptides listed a few rows away. For CJC-1295 the agency names actual events[2].
“FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”
[2]
For ipamorelin it goes further and names a death. For BPC-157 the same agency, on the same page, in the same format, records that it has identified no or only limited safety information and therefore cannot say whether the drug would cause harm. That is not a clean bill. It is a blank page where two neighbors have entries — and the two peptides with entries are CJC-1295 and ipamorelin, both of which have been through a trial. BPC-157 has not, so there was nowhere for an event to be recorded in the first place.
What the 2026 reviews concluded
Two reviews published this year cover the same menu these telehealth companies sell. A narrative review in Sports Medicine walks through AOD-9604, BPC-157, CJC-1295, GHK-Cu, ipamorelin, MOTS-c, sermorelin, tesamorelin and thymosin beta-4 together, and concludes that many of the unapproved ones show favorable tissue repair in animals while human safety data are scarce and the potential for serious harm is real[3]. A structured review in JBJS Reviews, covering human and translational evidence from 2020 through August 2025, puts BPC-157 and the thymosin derivatives in the same bucket as the growth-hormone secretagogues: investigational, with uncertain safety profiles and product quality concerns[4].
Both reviews raise product quality as a safety issue in its own right, separate from the molecule. That is the argument we take apart in what third-party testing actually proves, and it is the part of the risk a reader can do something about.
Who sells it, and what to ask them
Six priced lines on our roster are BPC-157, from four sellers: Live Vital, Blis MD, ElitePhysiqMD, and Pepti. For scale, the same kind of pattern finds sermorelin on 38 of the 190 sellers we have read, so a small count here is a small count, not a broken search.
- Which pharmacy compounds it, and whether that pharmacy is a state-licensed 503A or an FDA-registered outsourcing facility. Only the second is subject to current good manufacturing practice requirements[5].
- What the vial's beyond-use date is, and what it is based on.
- What the seller will do if you have a reaction — who you call, and whether they report it to the FDA.
- What the month-two price is, once any introductory rate ends. That one has nothing to do with safety and everything to do with what you will actually pay; our price method explains how we read it.
Questions people actually ask
What are the known side effects of BPC-157?
There is no measured list, because no clinical trial has ever compared BPC-157 against a placebo in people. Anything presented as a side-effect profile is drawn from animal studies or from what users report to each other, neither of which produces a rate.
Is BPC-157 considered safe?
The FDA's published position is that it has identified no or only limited safety information for the proposed routes of administration, and therefore lacks enough information to know whether the drug would cause harm in humans. That is a statement about the evidence, not a verdict about the molecule.
Why does the FDA name harms for other peptides but not this one?
Because harms get recorded where somebody was watching. CJC-1295 and ipamorelin were each given to people in a trial, so there were investigators collecting adverse events. BPC-157 has never been through one, so there is no file for an event to land in.
Does a compounded BPC-157 vial carry its own risks?
Yes, and they are separate from the molecule. The FDA's stated concerns about compounded peptides are immunogenicity, peptide-related impurities and characterizing the active ingredient at all. Those are manufacturing risks, and they apply to the vial in front of you rather than to the peptide in the abstract.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-11, "BPC 157" returned 228 records; with the animal indexing tag, 162; with the human indexing tag, 53; with safety, adverse, toxicity or tolerability terms, 49, falling to 20 when the human tag is added; with MeSH adverse-effects or toxicity subheadings, 36. The same safety-term query returned 2,088 for semaglutide and the subheading query 1,110, and the randomized-trial filter returned 316 for semaglutide and 0 for BPC-157 in the same session.
- 2.Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026On the page whose own face date reads April 22, 2026, the FDA records specific serious adverse events for CJC-1295 (increased heart rate and systemic vasodilatory reaction) and for ipamorelin acetate (including death), while for BPC-157 it records that it has identified no, or only limited, safety-related information and therefore lacks sufficient information to know whether the drug would cause harm.
- 3.Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine, 2026. PMID 41966639 · doi:10.1007/s40279-026-02437-0A 2026 narrative review covering AOD-9604, BPC-157, CJC-1295, GHK-Cu, ipamorelin, MOTS-c, sermorelin, tesamorelin, thymosin beta-4 and TB-500 concludes that many unapproved peptides show favorable tissue repair and metabolic outcomes in animal models while rigorous human safety data are scarce and there is potential for serious harm.
- 4.Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Reviews, 2026. PMID 42160466 · doi:10.2106/JBJS.RVW.26.00027A structured narrative review of human and translational evidence from January 2020 to August 2025 places regenerative peptides such as BPC-157 and thymosin derivatives, and growth hormone axis secretagogues such as CJC-1295, ipamorelin and tesamorelin, as investigational, with uncertain safety profiles and product quality concerns.
- 5.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements; drugs compounded by a licensed pharmacist in a state-licensed pharmacy under section 503A are not.
Key figures